Related references
Note: Only part of the references are listed.Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
E. B. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
Jing Zou et al.
NATURE COMMUNICATIONS (2022)
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022
Jonas Bjork et al.
EUROSURVEILLANCE (2022)
Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks
Tetsuya Akaishi et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2022)
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Edson D. Moreira et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Ori Magen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022
Kristin J. Marks et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
COVID-19 Vaccines in Infants, Children, and Adolescents
Yvonne A. Maldonado et al.
PEDIATRICS (2022)
Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
Tal Patalon et al.
NATURE COMMUNICATIONS (2022)
Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
Chaitanya Kurhade et al.
NATURE COMMUNICATIONS (2022)
Childcare and Employment Disruptions in 2020 Among Caregivers of Children With and Without Special Health Care Needs
Caleb Easterly et al.
JAMA PEDIATRICS (2022)
Risk Factors for Severity in Children with Coronavirus Disease 2019 A Comprehensive Literature Review
Sophia Tsabouri et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2021)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda et al.
LANCET (2021)
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
Robert W. Frenck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection
Lauren A. Paul et al.
JAMA PEDIATRICS (2021)
Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19-COVID-NET, 14 States, March 1-July 25, 2020
Lindsay Kim et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)